RA Capital Management »

Intellia Therapeutics shares owned by RA Capital Management

Quarter-by-quarter ownership of Intellia Therapeutics (NTLA) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Intellia Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Intellia Therapeutics held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Intellia Therapeutics by RA Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $77M 4.5M 16.92
2021-06-30 $2.4M 15k 161.93

More positions owned by RA Capital Management

Ascendis Pharma A/s Common Stock (ASND)
Parabilis Medicines Common Stock
Rhythm Pharmaceuticals Common Stock (RYTM)
Vaxcyte Common Stock (PCVX)
Sionna Therapeutics Common Stock (SION)
Tyra Biosciences Common Stock (TYRA)
Edgewise Therapeutics Common Stock (EWTX)
Newamsterdam Pharma Co Nv Common Stock (NAMS)
Hemab Therapeutics Holdings Common Stock
Septerna Common Stock (SEPN)
Bicara Therapeutics Common Stock (BCAX)
Mineralys Therapeutics Common Stock (MLYS)
Gh Research Common Stock (GHRS)
Disc Medicine Common Stock (IRON)
Spyglass Pharma Common Stock (SGP)

View all positions for RA Capital Management

Top funds holding Intellia Therapeutics

ARK Investment Management
BlackRock
Vanguard Portfolio Management
State Street Corporation
D. E. Shaw & Co
Vanguard Capital Management
Two Sigma Investments
FMR
RA Capital Management
Regeneron Pharmaceuticals
Geode Capital Management
Arrowstreet Capital, Limited Partnership
Sumitomo Mitsui Trust Holdings
Nikko Asset Management Americas
Dimensional Fund Advisors

View all funds holding Intellia Therapeutics